In consideration of the fact that copper chelating agents are already used for Wilson’s disease, are non-toxic and can deplete copper from all tissues of the body, this study provides an attractive framework for a new therapeutic strategy to target TGF-β and subsequently reducing both tumor growth and metastatic potential. Here, TGFB1 is linked to neoplasm.